Effects of minimal persistent inflammation on nasal mucosa of experimental allergic rhinitis

American Journal of Rhinology and Allergy

Volumn 24, Issue 1, 2010, Pages

  Lei, Fei ^a,b   Zhu, Dongdong ^a   Sun, Jianjun ^b   Dong, Zhen ^a  

^a JILIN UNIVERSITY   (China)

^b NAVY GENERAL HOSPITAL   (China)

Author keywords

Allergic rhinitis; Animal model; Histopathological changes; ICAM 1; Inflammation; Nasal mucosa; Tissue remodeling

Indexed keywords

ALCIAN BLUE; ANTIGEN; COLLAGEN; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA1;

ALLERGIC REACTION; ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; CELL INFILTRATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; EOSINOPHIL; GOBLET CELL; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; MALE; MUCOSA INFLAMMATION; NONHUMAN; NOSE MUCOSA; PROTEIN EXPRESSION; PROVOCATION TEST; SENSITIZATION; SNEEZING; STAINING;

ALLERGENS; ANIMALS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; EOSINOPHILS; EPITHELIAL CELLS; GUINEA PIGS; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MALE; MATRIX METALLOPROTEINASE 9; MICROSCOPY, CONFOCAL; NASAL MUCOSA; OVALBUMIN; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TRANSFORMING GROWTH FACTOR BETA1;

EID: 75749157744     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2010.24.3414     Document Type: Article

References (25)

1. Rivera J, and Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol 117:1214-1225, 2006.
2. Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 114 (suppl 5):135-138, 2004.
3. Venge P. Monitoring the allergic inflammation. Allergy 59:26-32, 2004.
4. Canonica GW, and Ciprandi G. Minimal persistent inflammation may be controlled by cetirizine. Ann Allergy Asthma Immunol 83: 445-448, 1999
5. Ciprandi G, Passalacqua G, Mincarini M, et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 79:507-511, 1997.
6. Ciprandi G, Buscaglia S, Pesce G, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 96:971-979, 1995.
7. Ricca V, Landi M, Ferrero P, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 105:54-57, 2000.
8. Ciprandi G, Tosca M, Passalacqua G, et al. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 87:222-226, 2001.
9. Tattersfield AE, Knox AJ, Britton JR, et al. Asthma. Lancet 360:1313-1322, 2002.
10. Bousquet J, Chanez P, Lacoste JY, et al. Asthma: A disease remodeling the airways. Allergy 47:3-11, 1992.
11. Gotwals PJ, Chi-Rosso G, Lidner V, et al. The alpha1beta1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganisation. J Clin Invest 97:2469-2477, 1996.
12. Lorimier S, Gillery P, Hornebeck W, et al. Tissue origin and extracellular matrix control neutral proteinase activity in human fibroblast three-dimensional cultures. J Cell Physiol 168:188-198, 1996.
13. Canonica GW. Treating asthma as an inflammatory disease. Chest 130(suppl 1):21S-28S, 2006.
14. Rehl RM, Balla AA, Cabay RJ, et al. Mucosal remodeling in chronic rhinosinusitis. Am J Rhinol 6:651-657, 2007.
15. Lim YS, Won TB, Shim WS, et al. Induction of airway remodeling of nasal mucosa by repetitive allergen challenge in a murine model of allergic rhinitis. Ann Allergy Asthma Immunol 98:22-31, 2007.
16. Ellis R, Leigh R, Southam D, et al. Morphometric analysis of mouse airways after chronic allergen challenge. Lab Invest 83:1285-1291, 2003.
17. Narita S, Asakura K, and Kataura A. Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. Int Arch Allergy Immunol 109: 161-166, 1996.
18. Storms W. Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: The possible role of leukotrienes. Ann Allergy Asthma Immunol 91:131-140, 2003.
19. Ricca V, Landi M, Ferrero P, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 104:54-57, 1999.
20. Laprise C, Laviolette M, Boutet M, et al. Asymptomatic airway hyperresponsiveness relationships with airway inflammation and remodelling. Eur Respir J 14:63-73, 1999.
21. Ciprandi G, Ricca V, Passalacqua G, et al. Seasonal rhinitis and azelastine: Long- or short-term treatment. J Allergy Clin Immunol 99:301-307, 1997.
22. Redington AE, Madden J, Frew AJ, et al. Transforming growth factor-[beta]1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 156:642-647, 1997.
23. Hoshino M, Nakamura Y, Sim J, et al. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 102:783-788, 1998.
24. Atkinson JJ, and Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 28:12-24, 2003.
25. Topal O, Erbek SS, Kiyici H, et al. Expression of metalloproteinases MMP-2 and MMP-9 in antrochoanal polyps. Am J Rhinol 4:339-342, 2008.